Prostate carcinoma screening in the county of Tyrol, Austria : Experience and results : Review of current data impacting early detection guidelines for prostate cancer.
American Cancer Society Workshop. Phoenix, Arizona (USA), 1997/03/10.
This article summarizes the experience and results of different prostate carcinoma screening projects using total prostate specific antigen (PSA) as the initial test and different diagnostic tests to improve specificity.
The seven projects studied included 1) a mass screening study using PSA as the initial test in 21,079 volunteers ; 2) an investigation of the usefulness of normal and age-referenced PSA cutoffs in 1618 men ; 3) a PSA-based screening study of 2272 asymptomatic blood donors ; 4) an investigation of the incidence and clinical significance of transitional zone carcinoma in 340 men with negative rectal examination findings and clearly visible prostatic zones on three-dimensional transrectal ultrasound ; 5) determination of percent free PSA in one retrospective and two prospective screening studies to define the optimal range of total PSA and determine the appropriate cutpoints for percent free PSA within this range ; 6) evaluation of the diagnostic benefit of PSA transitional zone density in 308 screening volunteers ; and 7) a study of the impact of PSA-based screening on the percentage of incidental prostate carcinoma diagnosed in 1543 men undergoing transurethal resection of the prostate.
1) Of the 21,078 volunteers, 1618 (8%) had elevated PSA levels.
Of these men, 778 (48%) underwent biopsies ; 197 biopsies (25%) were positive for prostate carcinoma and 135 patients underwent radical prostatectomy. (...)
Mots-clés Pascal : Carcinome, Prostate, Dépistage, Prévention, Homme, Antigène spécifique prostate, Marqueur tumoral, Sérum, Programme sanitaire, Autriche, Europe, Tumeur maligne, Appareil génital mâle pathologie, Appareil urinaire pathologie, Prostate pathologie
Mots-clés Pascal anglais : Carcinoma, Prostate, Medical screening, Prevention, Human, Prostate specific antigen, Tumoral marker, Serum, Sanitary program, Austria, Europe, Malignant tumor, Male genital diseases, Urinary system disease, Prostate disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0027044
Code Inist : 002B14D02. Création : 17/04/1998.